Suppr超能文献

乳腺核心活检中诊断的伴有非典型上皮增生的放射状瘢痕/复杂硬化性病变的转归:一项基于英国的多中心研究结果。

Outcome of radial scar/complex sclerosing lesion associated with epithelial proliferations with atypia diagnosed on breast core biopsy: results from a multicentric UK-based study.

机构信息

Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, UK

Faculty of Medicine, Menoufiya University, Al Minufya, Egypt.

出版信息

J Clin Pathol. 2019 Dec;72(12):800-804. doi: 10.1136/jclinpath-2019-205764. Epub 2019 Jul 26.

Abstract

AIMS

The clinical significance of radial scar (RS)/complex sclerosing lesion (CSL) with high-risk lesions (epithelial atypia) diagnosed on needle core biopsy is not well defined. We aimed at assessing the upgrade rate to ductal carcinoma in situ (DCIS) and invasive carcinoma on the surgical excision specimen in a large cohort with RS/CSL associated with atypia.

METHODS

157 women with a needle core biopsy diagnosis of a RS/CSL with atypia and follow-up histology were studied. Histological findings, including different forms of the atypical lesions and final histological outcome in the excision specimens, were retrieved and analysed, and the upgrade rates for malignancy and for invasive carcinoma were calculated.

RESULTS

69.43% of the cases were associated with atypical ductal hyperplasia (ADH) or atypia not otherwise classifiable, whereas lobular neoplasia was seen in 21.66%. On final histology, 39 cases were malignant (overall upgrade rate of 24.84%); 12 were invasive and 27 had DCIS. The upgrade differed according to the type of atypia and was highest for ADH (35%). When associated with lobular neoplasia, the upgrade rate was 11.76%. The upgrade rate's variability was also considerably lower when considering the upgrade to invasive carcinoma alone for any associated lesion.

CONCLUSIONS

The upgrade rate for ADH diagnosed on needle core biopsy with RS is similar to that of ADH without RS and therefore should be managed similarly. RS associated with lobular neoplasia is less frequently associated with malignant outcome. Most lesions exhibiting some degree of atypia showed a similar upgrade rate to invasive carcinoma. Management of RS should be based on the concurrent atypical lesion.

摘要

目的

在经皮穿刺核心活检诊断为伴有高危病变(上皮不典型)的放射状瘢痕(RS)/复杂硬化性病变(CSL)的临床意义尚不清楚。我们旨在评估在伴有不典型病变的 RS/CSL 大队列中,手术切除标本中向导管原位癌(DCIS)和浸润性癌升级的发生率。

方法

研究了 157 例经皮穿刺核心活检诊断为 RS/CSL 伴不典型病变且有随访组织学的女性。检索和分析了组织学发现,包括不同形式的不典型病变和切除标本中的最终组织学结果,并计算了恶性肿瘤和浸润性癌的升级率。

结果

69.43%的病例与非典型导管增生(ADH)或其他不可分类的不典型病变有关,而小叶肿瘤占 21.66%。在最终的组织学中,39 例为恶性(总升级率为 24.84%);12 例为浸润性癌,27 例为 DCIS。升级率因不典型病变的类型而异,ADH 的升级率最高(35%)。当与小叶肿瘤相关时,升级率为 11.76%。当仅考虑任何相关病变的浸润性癌升级时,升级率的变异性也明显较低。

结论

在伴有 RS 的经皮穿刺核心活检中诊断为 ADH 的升级率与不伴有 RS 的 ADH 相似,因此应进行类似的管理。与小叶肿瘤相关的 RS 较少发生恶性结局。大多数表现出一定程度不典型性的病变向浸润性癌的升级率相似。RS 的管理应基于同时存在的不典型病变。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验